Gemtuzumab ozogamicin (Mylotarg) for acute myeloid leukaemia - horizon scanning review
NHSC
Record ID 32005000239
English
Authors' objectives:
This study aims to assess the effectiveness of gemtuzumab ozogamicin (Mylotarg) for acute myeloid leukaemia.
Authors' recommendations:
Gemtuzumab ozogamicin (GO, Mylotarg, CMA 676) consists of a monoclonal antibody that directs chemotherapy (ozogamicin) at acute myeloid leukaemia cells. Mylotarg is currently in phase III trials and will be an add-on therapy for 2nd-line acute myeloid leukaemia (AML). Full results from ongoing randomised and open label phase III trials of patients with relapsed or refractory CD33 positive AML are awaited.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Acute Disease
- Antibodies, Monoclonal
- Leukemia, Myeloid
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.